Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Status:
Active, not recruiting
Trial end date:
2021-08-12
Target enrollment:
Participant gender:
Summary
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and
methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in
patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplant.
Both mycophenolate mofetil and reduced-dose methotrexate, in combination with a calcineurin
inhibitor, have been shown to be safe and effective in GVHD prevention with less toxicity
than standard dose methotrexate. It is not yet known, however, whether this combination of
mycophenolate mofetil and reduced-dose methotrexate with tacrolimus is more effective than
tacrolimus and standard dose methotrexate in preventing GVHD.